As of Thursday close, TG Therapeutics Inc.’s (NASDAQ:TGTX) stock was down -$0.36, moving down -3.35 percent to $10.39. The average number of shares traded per day over the past five days has been 6,471,180 shares. 3 times new highs have been achieved over the past 5 days, with a $0.69 gain in that time frame. In the last twenty days, the average volume was 7,795,080, while in the previous 50 days, it was 5,277,614.
Since last month, TGTX stock retreated -51.08%. Shares of the company fell to $9.15 on 08/11/23, the lowest level in the past month. A 52-week high of $35.67 was reached on 05/04/23 after having rallying from a 52-week low of $4.86. Since the beginning of this year, TGTX’s stock price has dropped by -12.17% or -$1.44, and marked a new high 22 times. However, the stock has declined by -70.87% since its 52-week high.
TGTX stock investors should be aware that TG Therapeutics Inc. (TGTX) stock had its last reported insider trading activity 7 days ago on Aug 11. WEISS MICHAEL S, the CEO and President of the company, purchased of 100,000 shares for $10.13 on Aug 11. It resulted in a $1,013,000 investment by the insider. Lonial Sagar sold 34,854 shares at an average price of $23.37 on Jun 23. The insider now owns 93,878 shares following the transaction. On Jun 02, Chief Financial Officer Power Sean A sold 73,647 shares at $26.70 apiece. The transaction was valued at $1,966,375.
Valuation Metrics
The stock’s beta is 2.13. Besides these, the trailing price-to-sales (P/S) ratio of 62.33, the price-to-book (PB) ratio of 35.83.
Financial Health
In the three months ended June 29, TG Therapeutics Inc.’s quick ratio stood at 2.50, while its current ratio was 2.90, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 2.41, and the total debt-to-equity ratio was 2.41. On the profitability front, the trailing twelve-month gross margin is 88.50% percent. Based on annual data, TGTX earned $2.52 million in gross profit and brought in $2.79 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -148.70%. Return on equity (ROE) for the past 12 months was -309.60%.
In TG Therapeutics Inc.’s quarter-end financial report for June 29, it reported total debt of $97.7 million against cash and short-term investments of $47.9 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. TGTX’s revenue rose 96.33% to $7.8 million during the quarter, while net income inched up to $16.07 million. While analysts expected TG Therapeutics Inc. to report -$0.25 quarterly earnings, the actual figure was -$0.34 per share, beating the consensus estimate by -36.00%. During the quarter, the company generated -$44.14 million in EBITDA. The liabilities of TG Therapeutics Inc. were 180.4 million at the end of its most recent quarter ended June 29, and its total debt was $109.02 million. The value of shareholders’ equity is $150.98 million.
Technical Picture
This quick technical analysis looks at TG Therapeutics Inc.’s (TGTX) price momentum. With a historical volatility rate of 80.52%, the RSI 9-day stood at 29.25% on 17 August.
With respect to its five-day moving average, the current TG Therapeutics Inc. price is up by +7.11% percent or $0.69. At present, TGTX shares trade -50.41% below its 20-day simple moving average and -29.32% percent below its 100-day simple moving average. However, the stock is currently trading approximately -60.78% below its SMA50 and +81.64% above its SMA200.
Stochastic coefficient K was 14.77% and Stochastic coefficient D was 15.52%, while ATR was 1.23. Given the Stochastic reading of 10.53% for the 14-day period, the RSI (14) reading has been calculated as 28.08%. As of today, the MACD Oscillator reading stands at 0.55, while the 14-day reading stands at -0.30.
Analyst Ratings
Goldman upgraded its rating on TG Therapeutics Inc. (NASDAQ: TGTX) to a Neutral in a note to investors on August 02, 2023. The analysts firm previously had a Sell rating on the stock.TG Therapeutics Inc. (TGTX) has been rated Overweight by analysts. According to 0 brokerage firms, TGTX is a sell, and 1 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 0 analysts rate TG Therapeutics Inc. stock as buy, with 7 recommending it as overweight.
With a median target price of $32.00, the current consensus forecast for the stock is $6.00 – $41.00. Based on these forecasts, analysts predict TG Therapeutics Inc. (TGTX) will achieve an average price target of $28.94.
